Regeneron Pharmaceuticals is set to acquire 23andMe for $256 million following its bankruptcy filing due to declining demand ...

Investors burned by President Trump’s trade fight now have to contend with a spending megabill that risks swelling the ...

The latest warnings from JPMorgan’s Jamie Dimon on geopolitical risks and tariffs have become par for the course.While he ...

Wall Street stocks edged higher Monday (May 19) after shrugging off a spike in US Treasury bond yields following Moody's ...

Home Depot doesn’t expect to raise prices because of tariffs, saying it has spent years diversifying the sources for the ...

Tech losses halted the S&P 500’s rally as Dow and Nasdaq also fell. Investors brace for inflation data and Fed signals to ...

Xeris Biopharma Holdings, Inc. , a growth-oriented biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, ...

World shares experienced a rally following China's decision to cut key interest rates in response to economic challenges ...

Japan's bond yield surge hints at global market risks. See how it impacts U.S. Treasuries, the yen, and top investments like ...

Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today announced a multi-year partnership with Sanofi , an innovative global healthcare company, and Regeneron , a ...

US stocks fell on Tuesday, with the S&P 500 snapping a six-day winning streak as bond yields crept higher, with gloomy comments from JPMorgan's boss dampening the mood.

Man Group plc slashed its stake in Regeneron Pharmaceuticals by over 40%, unloading 24,377 shares in Q4. Despite this selloff, Regeneron’s stock climbed 3.2%, shrugging off investor jitters like a ...